Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- First Posted Date
- 2003-09-17
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 40
- Registration Number
- NCT00025116
- Locations
- 🇨🇦
Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada
🇨🇦Ontario Cancer Institute, Toronto, Ontario, Canada
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
- Conditions
- Recurrent Lymphoepithelioma of the NasopharynxAnaplastic Thyroid CancerRecurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage III Squamous Cell Carcinoma of the LarynxStage IV Non-small Cell Lung CancerStage IVA Lymphoepithelioma of the OropharynxStage IVA Papillary Thyroid Cancer
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00068497
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Gefitinib in Treating Patients With Malignant Mesothelioma
- First Posted Date
- 2003-09-10
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00025207
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2013-10-24
- Target Recruit Count
- 71
- Registration Number
- NCT00066378
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium
🇧🇪Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium
Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
- Conditions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2012-07-18
- Target Recruit Count
- 44
- Registration Number
- NCT00066339
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT00026364
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- First Posted Date
- 2003-06-10
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 92
- Registration Number
- NCT00014170
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 65
- Registration Number
- NCT00062062
- Locations
- 🇺🇸
Promedica Cancer Center at Flower Hospital, Sylvania, Ohio, United States
🇺🇸Medical College of Ohio Cancer Institute, Toledo, Ohio, United States
🇺🇸St. Vincent Mercy Medical Center, Toledo, Ohio, United States
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT00062270
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
- Conditions
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸Institute for Drug Development, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.